NCT01525602View on ClinicalTrials.gov

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

February 28, 2018

Conditions
Solid Tumors
Interventions
DRUG

PLX3397

PLX3397 tablets, 200mg

DRUG

Paclitaxel

Paclitaxel IV

Trial Locations (8)

33136

Sylvester Comprehensive Cancer Center/UMHC, Miami

35233

University of Alabama at Birmingham, Birmingham

43210

Ohio State University, Columbus

44106

University Hospitals of Cleveland, Cleveland

55905

Mayo Clinic, Rochester

80045

University of Colorado, Anschutz Cancer Pavilion, Aurora

84112

University of Utah, Huntsman Cancer Institute, Salt Lake City

94143

Univeristy of California, San Francisco, San Francisco

Sponsors

Lead Sponsor

Daiichi Sankyo

Collaborators (1)

Plexxikon
All Listed Sponsors
collaborator

Plexxikon

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY

NCT01525602 - Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter